Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, shared a post on LinkedIn:
“Do you know why are we investing in tomorrow’s breakthroughs in lung cancer research and treatment through partnerships? At a time when research funding faces unprecedented challenges, LUNGevity Foundation is demonstrating what’s possible when organizations unite behind a common mission.
This month, LUNGevity announced seven strategic research awards totaling over $1 million. This has been made possible through strategic partnerships with Jill Feldman (EGFR Resisters), Lung Cancer Initiative (Paige Humble and Jenni Danai) and Lily Raines, Ph.D. (American Society for Radiation Oncology (ASTRO).
It absolutely takes a village:
EGFR Resisters is funding Dr. Elliott Brea’s groundbreaking CAR-T therapy for brain metastases – addressing a CNS complications seen in their community.
LCI is supporting Dr. Esther Redín Resano’s work on drug resistance – tackling the constant worry patients face about their tumors adapting to treatment.
ASTRO is backing Dr. Adam Grippin’s research combining mRNA vaccines with radiation therapy – advancing the future of combination treatments.
Plus four additional awards supporting veterans’ health equity (Lauren Kearney, MD, immunotherapy improvements (Dr. Michael Oh, UCLA), and obesity-cancer connections (Joyce Ogidigo PhD)
The bottom line is stark!! More than 226,000 Americans will be diagnosed with lung cancer this year. When federal funding tightens, strategic partnerships become essential to ensure that we have a vibrant workforce to support the needs of the lung cancer community.
Since 2012, LUNGevity has awarded 67 awards to foster the lung cancer workforce (starting with our Career Development Awards in 2012) with recipients going on to secure major NIH grants and even help get new FDA-approved treatments to patients.
Advances in lung cancer require researchers & and researchers need sustained investment, especially now.
I am beyond grateful to all our partners, supporters, and donors – for joining hands together. When patient advocates, medical societies, and research foundations join forces, they ensure research addresses the questions patients are actually asking, with expertise from the clinicians treating them. These seven researchers represent hope for the future, powered by partnerships united by a razor sharp focus – breakthrough scientists thrive when communities invest in their success together.”
More posts featuring Upal Basu Roy on OncoDaily.
